{
    "id": 2,
    "profileName": "BRAF V600K",
    "geneVariants": [
        {
            "id": 50,
            "fullName": "BRAF V600K",
            "impact": "missense",
            "proteinEffect": "gain of function"
        }
    ],
    "profileTreatmentApproaches": [
        {
            "id": 14667,
            "name": "MEK1 Inhibitor",
            "profileName": "BRAF V600K"
        },
        {
            "id": 14666,
            "name": "MEK inhibitor (Pan)",
            "profileName": "BRAF V600K"
        },
        {
            "id": 14668,
            "name": "MEK2 Inhibitor",
            "profileName": "BRAF V600K"
        },
        {
            "id": 14665,
            "name": "BRAF Inhibitor",
            "profileName": "BRAF V600K"
        },
        {
            "id": 14669,
            "name": "RAF Inhibitor (Pan)",
            "profileName": "BRAF V600K"
        }
    ],
    "createDate": "01/17/2014",
    "updateDate": "01/17/2014",
    "complexMolecularProfileEvidence": {
        "totalCount": 12,
        "complexMolecularProfileEvidence": [
            {
                "id": 5995,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22095,
                    "profileName": "BRAF V600K NRAS Q61K"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5971,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22095,
                    "profileName": "BRAF V600K NRAS Q61K"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5972,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22095,
                    "profileName": "BRAF V600K NRAS Q61K"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5981,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22095,
                    "profileName": "BRAF V600K NRAS Q61K"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5996,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22095,
                    "profileName": "BRAF V600K NRAS Q61K"
                },
                "therapy": {
                    "id": 4004,
                    "therapyName": "Dabrafenib + GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5974,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22095,
                    "profileName": "BRAF V600K NRAS Q61K"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7601,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25913,
                    "profileName": "BRAF V600K MAP2K1 P124Q"
                },
                "therapy": {
                    "id": 2804,
                    "therapyName": "VX-11e",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7602,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25913,
                    "profileName": "BRAF V600K MAP2K1 P124Q"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7598,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25913,
                    "profileName": "BRAF V600K MAP2K1 P124Q"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7599,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25916,
                    "profileName": "BRAF V600K MAP2K1 P124L"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7603,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25916,
                    "profileName": "BRAF V600K MAP2K1 P124L"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7600,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25916,
                    "profileName": "BRAF V600K MAP2K1 P124L"
                },
                "therapy": {
                    "id": 2804,
                    "therapyName": "VX-11e",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            }
        ]
    },
    "treatmentApproachEvidence": {
        "totalCount": 125,
        "treatmentApproachEvidence": [
            {
                "id": 11983,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, ASN003 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 371PD; NCT02961283).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 9947,
                        "pubMedId": null,
                        "title": "A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors",
                        "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5514,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SKLB646 inhibited proliferation and migration and induced apoptosis of triple-negative breast cancer (TNBC) cell lines in culture, and inhibited tumor growth in TNBC cell line xenograft models (PMID: 26721945).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3873,
                    "therapyName": "SKLB646",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5074,
                        "pubMedId": 26721945,
                        "title": "Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26721945"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 12658,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Stivarga (regorafenib) and Erbitux (cetuximab) resulted in a clinical benefit of either stable disease or partial response in 46% (11/24) of advanced solid tumor patients, including eight patients with colorectal cancer, and one patient with head and neck cancer, one with carcinoma of unknown primary, and one with glioblastoma (PMID: 28422758; NCT02095054).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1305,
                    "therapyName": "Cetuximab + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 10198,
                        "pubMedId": 28422758,
                        "title": "First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28422758"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 6265,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DHA and Stivarga (regorafenib) synergistically inhibited survival of kidney cancer cells in culture and reduced tumor growth in kidney cancer cell line xenograft models (PMID: 26921392).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4107,
                    "therapyName": "DHA + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 263,
                    "name": "kidney cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5514,
                        "pubMedId": 26921392,
                        "title": "Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26921392"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10378,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (5.6 vs 1.0 months), but no difference in overall survival (HR=0.87, p=0.79) compared to placebo in patients with synovial sarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 5485,
                    "name": "synovial sarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 15631,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (CONSIGN), Stivarga (regorafenib) treatment demonstrated safety profile and efficacy consistent with previous studies, median progression-free survival (PFS) was 2.7 months overall, 2.8 months in KRAS wild-type, and 2.5 months in KRAS mutant colorectal cancer patients, and with no difference in KRAS status between long and short PFS groups (PMID: 30190299; NCT01538680).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 13521,
                        "pubMedId": 30190299,
                        "title": "Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30190299"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1916,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III clinical trial (CORRECT) that supported FDA approval, Stivarga (regorafenib) demonstrated safety and improved overall survival compared to placebo (6.4 vs 5.0 months, HR=0.77, p=0.0052) in patients with refractory metastatic colorectal cancer (PMID: 23177514; NCT01103323).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 938,
                        "pubMedId": 23177514,
                        "title": "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23177514"
                    },
                    {
                        "id": 15580,
                        "pubMedId": null,
                        "title": "Stivarga (regorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10377,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (3.7 vs 1.8 months), but no difference in overall survival (HR=0.50, p=0.056) compared to placebo in patients with leiomyosarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1967,
                    "name": "leiomyosarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9823,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Stivarga (regorafenib) treatment in patients with non-small cell lung cancer resulted in stable disease (SD) in 76% (13/17) of patients, and one patient with SD experienced a progression free survival of 279 days and tumor reduction greater than 30% (J Clin Oncol 28:15s, 2010 (suppl; abstr 7585)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7646,
                        "pubMedId": null,
                        "title": "Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).",
                        "url": "http://meetinglibrary.asco.org/content/53410-74"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4544,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) showed antitumor activity in multiple murine xenograft models derived from melanoma, renal cell carcinoma, colorectal, breast, lung, pancreatic and ovarian tumor cell lines (PMID: 21170960).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 318,
                        "pubMedId": 21170960,
                        "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 2253,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Stivarga (regorafenib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 22421192).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1764,
                        "pubMedId": 22421192,
                        "title": "A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22421192"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8764,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) improved progression free survival compared to placebo in patients with refractory advanced oesophagogastric cancer (J Clin Oncol 33, 2015 (suppl; abstr 4003)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 5041,
                    "name": "esophageal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6734,
                        "pubMedId": null,
                        "title": "INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)\u2014Final overall and subgroup results.",
                        "url": "http://meetinglibrary.asco.org/content/147938-156"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1082,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Stivarga, (regorafenib), inhibited tumor growth in cell line xenograft models of glioblastoma multiforme (PMID: 21170960).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 318,
                        "pubMedId": 21170960,
                        "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10379,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (2.9 vs 1.0 months), but no difference in overall survival (HR=0.75, p=0.37) compared to placebo in patients with soft tissue sarcoma excluding liposarcoma, leiomyosarcoma, and synovial sarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1115,
                    "name": "sarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8763,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) improved progression free survival compared to placebo in patients with refractory advanced oesophagogastric cancer (J Clin Oncol 33, 2015 (suppl; abstr 4003)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10534,
                    "name": "stomach cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6734,
                        "pubMedId": null,
                        "title": "INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)\u2014Final overall and subgroup results.",
                        "url": "http://meetinglibrary.asco.org/content/147938-156"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10376,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment did not result in significant difference in median progression-free survival (1.1 vs 1.7 months) or overall survival (HR=1.57, p=0.21) compared to placebo in patients with liposarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3382,
                    "name": "liposarcoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1925,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III clinical trial (GRID) that supported FDA approval, Stivarga (regorafenib) demonstrated safety and improved progression free survival compared to placebo (4.8 vs 0.9 months, HR=0.27, p<0.0001) in patients with gastrointestinal stromal tumors (PMID: 23177515; NCT01271712).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9253,
                    "name": "gastrointestinal stromal tumor",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2400,
                        "pubMedId": 23177515,
                        "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23177515"
                    },
                    {
                        "id": 15580,
                        "pubMedId": null,
                        "title": "Stivarga (regorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7573,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) resulted in a PFS of 2.6 months compared to .9 months with placebo in gastric adenocarcinoma patients (PMID: 27325864).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3717,
                    "name": "gastric adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6437,
                        "pubMedId": 27325864,
                        "title": "Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325864"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9869,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (RESORCE) that supported FDA approval, treatment with Stivarga (regorafenib) following Nexavar (sorafenib) treatment resulted in improved overall survival (10.6 vs 7.8 months, HR=0.63) compared to Nexavar (sorafenib) followed by placebo in patients with hepatocellular carcinoma (PMID: 27932229; NCT01774344).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8404,
                        "pubMedId": 27932229,
                        "title": "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27932229"
                    },
                    {
                        "id": 15580,
                        "pubMedId": null,
                        "title": "Stivarga (regorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 855,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, RXDX-105 (CEP-32496) was tolerable and demonstrated preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2574)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6477,
                        "pubMedId": null,
                        "title": "A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.",
                        "url": "http://meetinglibrary.asco.org/content/165045-176"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8620,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, RXDX-105 (CEP-32496) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including 2 patients with heavily pretreated non-small cell lung cancer that achieved stable disease for greater that 6 months (AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C188).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6703,
                        "pubMedId": null,
                        "title": "Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers",
                        "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/C188"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 14947,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Belvarafenib (HM95573) treatment demonstrated safety and preliminary efficacy, resulted in unconfirmed partial response in 3% (1/31) and stable disease in 29% (9/31) of patients with advanced solid tumors harboring BRAF (45%), KRAS (45%) or NRAS (10%) mutations (May 20 2016) 2570-2570; NCT02405065).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7209,
                    "therapyName": "Belvarafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 11833,
                        "pubMedId": null,
                        "title": "First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.",
                        "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10473,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, WX-554 was well-tolerated and resulted in stable disease in 59% (20/34) and prolonged stable disease for greater than 6 months in 6% (2/34) of patients with advanced solid tumors (PMID: 27693888).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1058,
                    "therapyName": "WX-554",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8522,
                        "pubMedId": 27693888,
                        "title": "A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27693888"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10502,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/II trial, Refametinib (BAY86-9766) and Gemzar (gemcitabine) combination treatment resulted in an objective response rate of 23% and a disease control rate of 73% in patients with advanced pancreatic cancer (PMID: 27975152).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5545,
                    "therapyName": "Gemcitabine + Refametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8575,
                        "pubMedId": 27975152,
                        "title": "Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27975152"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1355,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Refametinib (BAY 86-9766) was well-tolerated and displayed some evidence of clinical benefit across several tumor types (PMID: 23434733).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 888,
                    "therapyName": "Refametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1066,
                        "pubMedId": 23434733,
                        "title": "Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434733"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 6406,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination treatment of Refametinib (BAY86-9766) and Nexavar (sorafenib) in patients with advanced solid tumors resulted in a disease control rate of 65.8% (25/38), specifically, 2.6% (1/38) experienced a partial response and 63.2% (24/38) demonstrated stable disease (PMID: 26644411).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5562,
                        "pubMedId": 26644411,
                        "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 6407,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, a patient with colorectal cancer demonstrated a durable partial response for 358 days when treated with the combination of Refametinib (BAY86-9766) and Nexavar (sorafenib) (PMID: 26644411).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5562,
                        "pubMedId": 26644411,
                        "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 6408,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, 43.8% (7/16) of hepatocellular carcinoma patients treated with a combination of Refametinib (BAY86-9766) and Nexavar (sorafenib) demonstrated stable disease (PMID: 26644411).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5562,
                        "pubMedId": 26644411,
                        "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1286,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BI-847325 demonstrated safety and some efficacy in a variety of advanced solid tumors (Mol Cancer Ther 2013;12(11 Suppl):B281).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 998,
                        "pubMedId": null,
                        "title": "Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.",
                        "url": "http://mct.aacrjournals.org/content/12/11_Supplement/B281.meeting_abstract"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4497,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BI-847325 treatment resulted in stable disease in 30% (21/69) of patients with advanced solid tumors, and one partial response for 67 days in a patient with esophageal cancer (PMID: 26650227).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4389,
                        "pubMedId": 26650227,
                        "title": "A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26650227"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4073,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BI-847325 treatment resulted in stable disease in 30% (21/69) of patients with advanced solid tumors, and one partial response for 67 days in a patient with esophageal cancer (PMID: 26650227).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 5041,
                    "name": "esophageal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4389,
                        "pubMedId": 26650227,
                        "title": "A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26650227"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9752,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of AZD8055 and Mekinist (trametinib) enhanced the sensitivity of ovarian cancer cells to ABT-737 in culture, resulting in greater apoptotic activity and cell cycle arrest when compared to Mekinist (trametinib) alone (PMID: 27980105).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5191,
                    "therapyName": "ABT-737 + AZD8055 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7524,
                        "pubMedId": 27980105,
                        "title": "The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980105"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9753,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of BEZ235 and Mekinist (trametinib) enhanced the sensitivity of ovarian cancer cells to ABT-737 in culture, resulting in decreased cell viability (PMID: 27980105).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5192,
                    "therapyName": "ABT-737 + BEZ235 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7524,
                        "pubMedId": 27980105,
                        "title": "The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980105"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9754,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Mekinist (trametinib) enhanced the sensitivity of ovarian cancer cells to ABT-737 in culture, resulting in decreased cell viability (PMID: 27980105).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5193,
                    "therapyName": "ABT-737 + MK2206 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7524,
                        "pubMedId": 27980105,
                        "title": "The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980105"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 3631,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Mekinist (trametinib) and Afuresertib (GSK2110183) was not well-tolerated in patients with advanced solid tumors (PMID: 25417902).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3204,
                    "therapyName": "Afuresertib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3920,
                        "pubMedId": 25417902,
                        "title": "Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25417902"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 11099,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination therapy of AMG 232 and Mekinist (trametinib) in 15 patients with metastatic cutaneous melanoma without a BRAF V600 mutation resulted in a partial response in 2 patients, stable disease in 11 patients, and progressive disease in 2 patients, and of the 15 patients, 11 experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1454,
                    "therapyName": "AMG 232 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9073,
                        "pubMedId": null,
                        "title": "Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)",
                        "url": "http://abstracts.asco.org/199/AbstView_199_181299.html"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 11124,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and AZ628 resulted in greater inhibition of Mek and apoptosis in a non-BRAF V600 mutant lung cancer cell line in culture compared to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (J Clin Oncol 35, 2017 (suppl; abstr e23154)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4795,
                    "therapyName": "AZ628 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1324,
                    "name": "lung cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 9096,
                        "pubMedId": null,
                        "title": "Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer",
                        "url": "http://abstracts.asco.org/199/AbstView_199_191661.html"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1694,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, ovarian cancer patients demonstrated an objective response rate of 21% (6/21), including 1 complete response and 5 partial responses, to treatment with Buparlisib (BKM120) in combination with Mekinist (trametinib) (PMID: 25500057)",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1974,
                    "therapyName": "Buparlisib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1794,
                        "pubMedId": 25500057,
                        "title": "A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500057"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10761,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in partial response in 1 patient and stable disease in 3 patients within the subset of 5 evaluable patients with squamous non-small cell lung cancer patients (PMID: 27876675).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1264,
                    "therapyName": "Docetaxel + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3907,
                    "name": "lung squamous cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8810,
                        "pubMedId": 27876675,
                        "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10760,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 21% (10/47, all partial responses) and stable disease in 43% (20/47) of patients with non-small cell lung cancer (PMID: 27876675).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1264,
                    "therapyName": "Docetaxel + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8810,
                        "pubMedId": 27876675,
                        "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1255,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, Mekinist (trametinib) enhanced the efficacy of Adrucil (fluorouracil) in colorectal cancer cells in culture (PMID: 23438367).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1113,
                    "therapyName": "Fluorouracil + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 181,
                        "pubMedId": 23438367,
                        "title": "Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23438367"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 2062,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, the combination of Mekinist (trametinib) and Gemzar (gemcitabine) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors (PMID: 23583440).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1269,
                    "therapyName": "Gemcitabine + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 977,
                        "pubMedId": 23583440,
                        "title": "A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23583440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 3618,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib clinical trial, the combination of Mekinist (trametinib) and Gemzar (gemcitabine) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors, including one complete response in a patient with breast cancer (PMID: 23583440).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1269,
                    "therapyName": "Gemcitabine + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 977,
                        "pubMedId": 23583440,
                        "title": "A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23583440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1260,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, a partial response was seen in 30% (3/11) of  patients with pancreatic cancer after treatment with Mekinist (trametinib) in combination with Gemzar (gemcitabine) (PMID: 23583440).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1269,
                    "therapyName": "Gemcitabine + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 977,
                        "pubMedId": 23583440,
                        "title": "A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23583440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9080,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) effectively inhibited tumor angiogenesis and growth in cell line xenograft models of renal cell carcinoma (PMID: 26487278).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1310,
                    "therapyName": "Pazopanib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6896,
                        "pubMedId": 26487278,
                        "title": "Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26487278"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10474,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib/II trial, the combination of Votrient (pazopanib) and Mekinist (trametinib) demonstrated safety and resulted in partial response in 8% (2/25) and stable disease in 48% (12/25) of patients with advanced soft tissue sarcomas, but did not improve the 4 month progression-free survival rate over Votrient (pazopanib) alone (PMID: 28377484).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1310,
                    "therapyName": "Pazopanib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1115,
                    "name": "sarcoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 8528,
                        "pubMedId": 28377484,
                        "title": "Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28377484"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10764,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate of 14% (6/42, all partial responses) and stable disease in 55% (23/42) of patients with non-small cell lung cancer (PMID: 27876675).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1266,
                    "therapyName": "Pemetrexed + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8810,
                        "pubMedId": 27876675,
                        "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9078,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination of Mekinist (trametinib) and Sutent (sunitinib) effectively inhibited tumor angiogenesis and growth in cell line xenograft models of Sutent (sunitinib)-refractory renal cell carcinoma (PMID: 26487278).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4874,
                    "therapyName": "Sunitinib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6896,
                        "pubMedId": 26487278,
                        "title": "Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26487278"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 11972,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, 42% (11/26) of pancreatic cancer patients demonstrated a decrease in tumor formation when treated with Mekinist (trametinib) (PMID: 22805291).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 445,
                        "pubMedId": 22805291,
                        "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16746,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease as best response in 50% (8/16) of patients with uveal melanoma (PMID: 22805292; NCT00687622).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 6039,
                    "name": "uveal melanoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 233,
                        "pubMedId": 22805292,
                        "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10813,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Mekinist (trametinib) treatment in patients with oral cavity squamous cell carcinoma was associated with decreased phosphorylation of Erk1/2 and reduced CD44 expression, and resulted in a partial response in 65% (11/17), stable disease in 29% (5/17), and progressive disease in 1 patient (6%) (PMID: 28151720).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 50866,
                    "name": "oral squamous cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8851,
                        "pubMedId": 28151720,
                        "title": "Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151720"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 2858,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Trametinib (GSK1120212) and Uprosertib (GSK2141795) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol (Meeting Abstracts) 2011 29: 3085).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3509,
                        "pubMedId": null,
                        "title": "Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).",
                        "url": "http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/3085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10718,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO4987655 demonstrated safety and preliminary clinical activity in Japanese patients with advanced solid tumors, including 1 partial response in a patient with esophageal cancer and 7 patients achieving progression-free survival for greater than 16 weeks (PMID: 25809858).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 903,
                    "therapyName": "RO4987655",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8783,
                        "pubMedId": 25809858,
                        "title": "Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25809858"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4011,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO4987655 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 22767668).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 903,
                    "therapyName": "RO4987655",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4366,
                        "pubMedId": 22767668,
                        "title": "Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22767668"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10457,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in complete response in 3.3% (1/30) and partial response in 6.7% (2/30) of patients with biliary tract cancer, with estimated progression free survival of 2.1 months and overall survival of 4.8 months (PMID: 28152546).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4607,
                    "name": "biliary tract cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8465,
                        "pubMedId": 28152546,
                        "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 736,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in complete response in 1% (1/91), partial response in 2% (2/91), and stable disease with median duration of 3.94 months in 36% (33/91) of patients with advanced solid tumors (PMID: 28152546).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8465,
                        "pubMedId": 28152546,
                        "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7047,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, the combination of Binimetinib (MEK162) and FOLFOX chemotherapy demonstrated manageable toxicity and preliminary efficacy in metastatic colorectal cancer patients with chemotherapy resistance (J Clin Oncol 34, 2016 (suppl; abstr 2544)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2217,
                    "therapyName": "Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Binimetinib  + FOLFOX"
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6053,
                        "pubMedId": null,
                        "title": "A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.",
                        "url": "http://meetinglibrary.asco.org/content/162654-176"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16186,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, combination therapy with Taxol (paclitaxel) and Mektovi (binimetinib) was tolerable and resulted in an objective response rate of 18% (5/28, 1 complete response, 4 partial responses) and a clinical benefit rate of 57% (16/28, best overall response of stable disease or better) in patients with platinum resistant/refractory epithelial ovarian cancer, and clinical benefit was observed in all patients with MAPK pathway alterations (n=4) (PMID: 29844129; NCT01649336).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2010,
                    "therapyName": "Binimetinib + Paclitaxel",
                    "synonyms": null
                },
                "indication": {
                    "id": 2152,
                    "name": "ovary epithelial cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 14290,
                        "pubMedId": 29844129,
                        "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 2063,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and AZD8055 worked synergistically to inhibit tumor growth in xenograft models of rhabdomyosarcoma (PMID: 23918606).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2561,
                    "therapyName": "AZD8055 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3247,
                    "name": "rhabdomyosarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2538,
                        "pubMedId": 23918606,
                        "title": "Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23918606"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10478,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Selumetinib (AZD6244) and Deticene (dacarbazine) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with partial responses in 17% (4/23) and stable disease for greater than 6 weeks in 65% (15/23) of patients (PMID: 28264648).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1432,
                    "therapyName": "Dacarbazine + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8532,
                        "pubMedId": 28264648,
                        "title": "A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28264648"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10477,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Selumetinib (AZD6244) and Taxotere (docetaxel) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with partial responses in 22% (6/27) and stable disease for greater than 6 weeks in 52% (14/27) of patients (PMID: 28264648).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1117,
                    "therapyName": "Docetaxel + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8532,
                        "pubMedId": 28264648,
                        "title": "A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28264648"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 3762,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of KW-2450 and Selumetinib worked synergistically to inhibit growth of triple-negative breast cancer cells in culture (PMID: 26443806).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3295,
                    "therapyName": "KW-2450 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4114,
                        "pubMedId": 26443806,
                        "title": "Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26443806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10481,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, the combination of Selumetinib (AZD6244) and MK2206 did not result in improved median overall survival compared to mFOLFOX therapy (3.9 mo vs. 6.7 mo) or improved median progression-free survival (1.9 mo vs 2.0 mo) in patients with pancreatic adenocarcinoma (PMID: 27978579).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1098,
                    "therapyName": "MK2206 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4074,
                    "name": "pancreatic adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 8534,
                        "pubMedId": 27978579,
                        "title": "Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27978579"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4903,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial, Selumetinib (AZD6244) demonstrated safety and tolerability but had minimal activity with a complete response achieved in 5.6% (2/36) of refractory multiple myeloma patients (PMID: 26446942).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9538,
                    "name": "multiple myeloma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 4786,
                        "pubMedId": 26446942,
                        "title": "A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446942"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1150,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a meta-analysis, Selumetinib (AZD6244) was shown to have modest clinical efficacy as a monotherapy in a variety of solid tumors (PMID: 24716986).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 899,
                        "pubMedId": 24716986,
                        "title": "Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24716986"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8396,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with Selumetinib (AZD6244) demonstrated safety and preliminary efficacy patients with advanced solid tumors, with several patients achieving prolonged stable disease (PMID: 18390968).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3898,
                        "pubMedId": 18390968,
                        "title": "Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/18390968"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16749,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Selumetinib (AZD6244) improved median progression-free survival (15.9 vs 7 weeks, HR=0.46, p<0.001) but not overall survival (11.8 vs 9.1 months, HR=0.66, p=0.09) compared to chemotherapy in patients with uveal melanoma, but also caused high adverse event rate (PMID: 24938562; NCT01143402).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 6039,
                    "name": "uveal melanoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8678,
                        "pubMedId": 24938562,
                        "title": "Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24938562"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 3619,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with Selumetinib (AZD6244) demonstrated safety and preliminary efficacy patients with advanced solid tumors, including patients with breast cancer, with several patients achieving prolonged stable disease (PMID: 18390968).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3898,
                        "pubMedId": 18390968,
                        "title": "Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/18390968"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8533,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the Mek inhibitor Selumetinib (AZD6244) inhibited tumorigenicity and invasiveness of triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26384399).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6682,
                        "pubMedId": 26384399,
                        "title": "MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26384399"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 15055,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination therapy of SHP099 and Selumetinib (AZD6244) led to decreased cell viability and reduced colony formation in triple-receptor negative breast cancer cells in culture and tumor regression in xenograft models (PMID: 30045908).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7400,
                    "therapyName": "Selumetinib + SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 12547,
                        "pubMedId": 30045908,
                        "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 15056,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination therapy of Selumetinib (AZD6244) and SHP099 resulted in decreased colony formation and reduced cell viability in ovarian cancer cells in culture and  inhibition of tumor growth and reduced tumor angiogenesis in a patient-derived xenograft (PDX) model of ovarian cancer (PMID: 30045908).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7400,
                    "therapyName": "Selumetinib + SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 12547,
                        "pubMedId": 30045908,
                        "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 15040,
                "approvalStatus": "Preclinical - Pdx & cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of SHP099 and Selumetinib (AZD6244) resulted in greater sensitivity compared to either agent alone in pancreatic ductal adenocarcinoma cells, demonstrating decreased cell viability and reduced colony formation in culture and decreased tumor growth in patient-derived xenograft (PDX) models (PMID: 30045908).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7400,
                    "therapyName": "Selumetinib + SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 3498,
                    "name": "pancreatic ductal adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 12547,
                        "pubMedId": 30045908,
                        "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8713,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) and Selumetinib (AZD6244) combination treatment resulted in partial response in 15% (4/27) and stable disease in 48% (13/27) of hepatocellular carcinoma patients (PMID: 27681866).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4801,
                    "therapyName": "Selumetinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6716,
                        "pubMedId": 27681866,
                        "title": "A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681866"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 2717,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, AZD8330 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors (PMID: 23433846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 658,
                    "therapyName": "AZD8330",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3433,
                        "pubMedId": 23433846,
                        "title": "A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23433846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 441,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Pimasertib in combination with Gemzar (gemcitabine) demonstrated safety and efficacy in metastatic pancreatic adenocarcinoma patients (PMID: 23846936).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3526,
                    "therapyName": "Gemcitabine + Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4074,
                    "name": "pancreatic adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 186,
                        "pubMedId": 23846936,
                        "title": "Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23846936"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4615,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with Pimasertib (MSC1936369B) followed by Gemzar (gemcitabine) resulted in enhanced inhibition of proliferation and induction of apoptosis in pancreatic cell lines in culture (PMID: 26228206).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3526,
                    "therapyName": "Gemcitabine + Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4571,
                        "pubMedId": 26228206,
                        "title": "The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26228206"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4044,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Pimasertib (MSC1936369B) demonstrated safety and some preliminary anti-tumor activity in patients with advanced solid tumors (J Clin Oncol 28:15s, 2010 (suppl; abstr 2504)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 871,
                    "therapyName": "Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4385,
                        "pubMedId": null,
                        "title": "First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors",
                        "url": "http://meetinglibrary.asco.org/content/43866-74"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10475,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of SL327 and Sutent (sunitinib) worked additively to decrease viability, induce apoptosis, and decrease migration of Taxotere (docetaxel)-resistant anaplastic thyroid cancer cell lines in culture, and to inhibit tumor growth in xenograft models (PMID: 28178630)",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5526,
                    "therapyName": "SL327 + Sunitinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8529,
                        "pubMedId": 28178630,
                        "title": "Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178630"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4019,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, TAK-733 demonstrated safety and some preliminary efficacy in patients with advanced solid tumors with partial response in 5% (2/41) and stable disease in 37% (15/41) of patients (PMID: 27650277).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 932,
                    "therapyName": "TAK-733",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4369,
                        "pubMedId": null,
                        "title": "Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.",
                        "url": "http://meetinglibrary.asco.org/content/112399-132"
                    },
                    {
                        "id": 8527,
                        "pubMedId": 27650277,
                        "title": "A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27650277"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 13915,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 7% (7/84) of patients with metastatic colorectal cancer, with a median duration of response of 14.8 months, a disease control rate of 31% (26/84), a median progression-free survival of 1.9 months, and a median overall survival of 10.0 months (Journal of Clinical Oncology 36, no. 4_suppl (February 1 2018) 560-560; NCT01988896).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 11357,
                        "pubMedId": null,
                        "title": "A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).",
                        "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.560"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 14626,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (IMblaze370), Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment did not improve median overall survival (8.9 vs 8.5 months, HR=1.00, p=0.987) compared to Stivarga (regorafenib) in patients with chemotherapy-refractory metastatic colorectal cancer, 91.7% of whom were microsatellite stable or microsatellite instability-low (Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018; NCT02788279).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 11788,
                        "pubMedId": null,
                        "title": "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer",
                        "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy208.003/5043313"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16569,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, and at 11.9 months the median duration of response and progression-free survival were not yet reached (PMID: 30867592; NCT01953926).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60073,
                    "name": "lymphatic system cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 14632,
                        "pubMedId": 30867592,
                        "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1839,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Cotellic (cobimetinib) treatment resulted in stable disease for five months or more in five patients with advanced solid tumors (PMID: 27424159).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2262,
                        "pubMedId": null,
                        "title": "Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors",
                        "url": "http://cancerres.aacrjournals.org/content/71/8_Supplement/4716.short"
                    },
                    {
                        "id": 10025,
                        "pubMedId": 27424159,
                        "title": "A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27424159"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1135,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) induced cell death in several human melanoma cell lines in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 353,
                        "pubMedId": 22084396,
                        "title": "Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22084396"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1367,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial Ipatasertib (GDC-0068), in combination with the Mek inhibitor Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Cancer Res, October 1, 2014 74; CT328).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1160,
                    "therapyName": "Cobimetinib + Ipatasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1084,
                        "pubMedId": null,
                        "title": "Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors",
                        "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/CT328.short"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 4074,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, CI-1040 treatment resulted in median stable disease for 5.5 months in 28% (19/66) of patients with advanced solid tumors (including colorectal, non-small-cell lung, pancreatic, melanoma, and kidney) and partial response in 1 pancreatic cancer patient (PMID: 16009947).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4390,
                        "pubMedId": 16009947,
                        "title": "Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/16009947"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10195,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of BI 2536 and PD-0325901 resulted in greater inhibition of cell proliferation in glioblastoma cells in culture compared to treatment with either agent alone (PMID: 26573800).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5423,
                    "therapyName": "BI2536 + PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8161,
                        "pubMedId": 26573800,
                        "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 438,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I study, PD-325901 demonstrated efficacy but toxicity at current dose was unacceptable (PMID: 21516509).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 170,
                        "pubMedId": 21516509,
                        "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1354,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, PD-0325901 demonstrated preliminary clinical activity in patients with advanced solid tumors, however late-onset dose-limiting toxicities were encountered (PMID: 20215549).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1064,
                        "pubMedId": 20215549,
                        "title": "Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20215549"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 439,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, PD-0325901 demonstrated some efficacy, however, the dose administered resulted in a significant degree of toxicity (PMID: 21516509).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 170,
                        "pubMedId": 21516509,
                        "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1129,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, PD-0325901 demonstrated some efficacy in previously treated melanoma patients, however, there was significant toxicity above 10 mg BID (PMID: 21516509).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 170,
                        "pubMedId": 21516509,
                        "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1846,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PD-0325901, in combination with PF-04691502, delayed tumor growth in patient-derived xenograft models of bladder cancer (PMID: 24442130).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2434,
                    "therapyName": "PD-0325901 + PF-04691502",
                    "synonyms": null
                },
                "indication": {
                    "id": 11054,
                    "name": "urinary bladder cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2265,
                        "pubMedId": 24442130,
                        "title": "Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24442130"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10719,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO5126766 demonstrated safety and some preliminary activity in Japanese patients with advanced solid tumors, with 42% (5/12) of patients achieving stable disease (PMID: 23860959).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2011,
                    "therapyName": "RO5126766",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8784,
                        "pubMedId": 23860959,
                        "title": "Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23860959"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 2753,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO5126766 demonstrated safety and preliminary efficacy in patients with a variety of solid tumors (PMID: 22761467).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2011,
                    "therapyName": "RO5126766",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3457,
                        "pubMedId": 22761467,
                        "title": "First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22761467"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7395,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a colon cancer cell line treated with AZ628 demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4487,
                    "therapyName": "AZ628 + CPI-455",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6341,
                        "pubMedId": 27214401,
                        "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7755,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the treatment combination of Avastin (bevacizumab) and Nexavar (sorafenib) in patients with advanced solid tumors resulted in stable disease in 25% (29/115) of patients and a partial response in 5% (6/115) of patients (PMID: 25363205).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4517,
                    "therapyName": "Bevacizumab + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6478,
                        "pubMedId": 25363205,
                        "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7562,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab) did not result in a significant improvement in progression-free survival compared to treatment with Avastin (bevacizumab) as a single agent (9.2 months vs 7.4 months) in patients with renal clear cell carcinoma (PMID: 26077237).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4517,
                    "therapyName": "Bevacizumab + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4467,
                    "name": "clear cell renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6421,
                        "pubMedId": 26077237,
                        "title": "BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26077237"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10320,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) in combination with Platinol (cisplatin) and Gemzar (gemcitabine) resulted in pathologic complete response in 42.2% (19/45) of patients with muscle-invasive urothelial bladder cancer (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5462,
                    "therapyName": "Cisplatin + Gemcitabine + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 6477,
                    "name": "invasive bladder transitional cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8305,
                        "pubMedId": null,
                        "title": "Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.",
                        "url": "http://meetinglibrary.asco.org/content/179076-197"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10797,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with the combination of CVX-060 and Nexavar (sorafenib) resulted in increased tumor growth inhibition compared to either agent alone in a colon cancer cell line xenograft model (PMID: 21233403).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5623,
                    "therapyName": "CVX-060 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8820,
                        "pubMedId": 21233403,
                        "title": "Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21233403"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8714,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial, the combination treatment of Nexavar (sorafenib) with Tarceva (erlotinib) compared to Nexavar (sorafenib) plus placebo did not demonstrate an improved overall survival and time to progression in patients with hepatocellular carcinoma (PMID: 25547503).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4800,
                    "therapyName": "Erlotinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6715,
                        "pubMedId": 25547503,
                        "title": "SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25547503"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5048,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Gilenya (fingolimod) worked synergistically with Nexavar (sorafenib) to inhibit growth and induce apoptosis in hepatocellular carcinoma cell lines in culture (PMID: 26516583).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3739,
                    "therapyName": "Fingolimod + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4862,
                        "pubMedId": 26516583,
                        "title": "FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26516583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1358,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Acrichine (quinacrine) and Adrucil (5-fluorouracil) synergistically enhanced the cytotoxicity of Nexavar (sorafenib) in human colorectal cancer cell lines in culture (PMID: 21725213).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4643,
                    "therapyName": "Fluorouracil + Quinacrine + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 172,
                        "pubMedId": 21725213,
                        "title": "Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725213"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 652,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Nexavar (sorafenib) in combination with Adrucil (fluorouracil) displayed safety and efficacy in advanced solid tumors, including colon cancer (PMID: 22232731).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1086,
                    "therapyName": "Fluorouracil + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 305,
                        "pubMedId": 22232731,
                        "title": "Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22232731"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 513,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Nexavar (sorafenib) in combination with Adrucil (fluorouracil) displayed safety and efficacy in advanced solid tumors, including colon cancer (PMID: 22232731).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1086,
                    "therapyName": "Fluorouracil + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 305,
                        "pubMedId": 22232731,
                        "title": "Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22232731"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 6064,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of GW5074 and Nexavar (sorafenib) induced cell death in several tumor cell lines, and phosphorylation of DAPK at amino acid S308 correlated positively with response to therapy (PMID: 26100670).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3376,
                    "therapyName": "GW5074 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4259,
                        "pubMedId": 26100670,
                        "title": "Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26100670"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 3877,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of GW5074 and Nexavar (sorafenib) worked synergistically to induce cell death in renal cell carcinoma cells in culture and inhibited tumor growth in xenograft and spontaneous mouse models of renal cell carcinoma (PMID: 26100670).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3376,
                    "therapyName": "GW5074 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4259,
                        "pubMedId": 26100670,
                        "title": "Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26100670"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7243,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, the combination of Revlimid (lenalidomide) and Nexavar (sorafenib) was not well-tolerated and did not demonstrate clinical activity in patients with hepatocellular carcinoma, and the study was terminated early due to toxicity (PMID: 27256874).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4426,
                    "therapyName": "Lenalidomide + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6255,
                        "pubMedId": 27256874,
                        "title": "Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256874"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9341,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, addition of Glucophage (metformin) sensitized hepatocellular carcinoma cells to Nexavar (sorafenib) induced apoptosis in culture, resulted in suppression of postoperative intrahepatic recurrence and lung metastasis in cell line xenograft models (PMID: 26957312).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4982,
                    "therapyName": "Metformin + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7120,
                        "pubMedId": 26957312,
                        "title": "Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26957312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7307,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial in patients with advanced solid tumors, the combination of Alimta (pemetrexed) and Nexavar (sorafenib) demonstrated safety and preliminary efficacy in patients with breast cancer, with 58% (7/12) of breast cancer patients achieving objective response or stable disease (PMID: 27213589).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1482,
                    "therapyName": "Pemetrexed + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6305,
                        "pubMedId": 27213589,
                        "title": "Phase I study of pemetrexed with sorafenib in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27213589"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7305,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, the combination of Alimta (pemetrexed) and Nexavar (sorafenib) demonstrated safety and some preliminary efficacy in patients with advanced solid tumors, with an objective response rate of 15% (5/33) and stable disease in 45% (15/33) of patients (PMID: 27213589).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1482,
                    "therapyName": "Pemetrexed + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6305,
                        "pubMedId": 27213589,
                        "title": "Phase I study of pemetrexed with sorafenib in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27213589"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7306,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial in patients with advanced solid tumors, the combination of Alimta (pemetrexed) and Nexavar (sorafenib) demonstrated safety and preliminary efficacy in patients with triple-receptor breast cancer (TNBC), with 60% (3/5) of TNBC patients demonstrating an objective response and 100% (5/5) of patients achieving stable disease or better (PMID: 27213589).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1482,
                    "therapyName": "Pemetrexed + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6305,
                        "pubMedId": 27213589,
                        "title": "Phase I study of pemetrexed with sorafenib in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27213589"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 593,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with the combination of Stivarga (regorafenib) PK-866 resulted in increased cell death in a variety of solid tumor cell lines in culture (PMID: 23877009).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4494,
                    "therapyName": "PX-866 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 346,
                        "pubMedId": 23877009,
                        "title": "Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23877009"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 6523,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/II trial, the combination of Resminostat (4SC-201) and Nexavar (sorafenib) demonstrated increased efficacy compared to Resminostat (4SC-201) alone in advanced hepatocellular carcinoma patients, resulting in an improved progression-free survival rate of 62.5% vs. 12.5%, a median time to progression of 4.1 vs. 1.8 months, and an overall survival of 8.0 vs. 6.5 months (PMID: 26952006).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4135,
                    "therapyName": "Resminostat + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5684,
                        "pubMedId": 26952006,
                        "title": "Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26952006"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 9224,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of SF1126 and Nexavar (sorafenib) was synergistic or additive in inhibiting proliferation of hepatocellular carcinoma cell lines in culture, and demonstrated increased efficacy in hepatocellular carcinoma cell line xenograft models compared to SF1126 alone (PMID: 23355037).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4956,
                    "therapyName": "SF1126 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7040,
                        "pubMedId": 23355037,
                        "title": "An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23355037"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1970,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) resulted in an improved median progression-free survival of 167 days in patients with renal cell carcinoma (PMID: 17189398).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2419,
                        "pubMedId": 17189398,
                        "title": "Sorafenib for the treatment of advanced renal cell carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/17189398"
                    },
                    {
                        "id": 15587,
                        "pubMedId": null,
                        "title": "Nexavar (sorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 8610,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 13% (4/31), stable disease in 52% (16/31), a median progression-free survival of 4.9 months and an overall survivals of 9.7 months in gastrointestinal stromal tumor patients who failed prior tyrosine kinase inhibitors (PMID: 22270258).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9253,
                    "name": "gastrointestinal stromal tumor",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6697,
                        "pubMedId": 22270258,
                        "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270258"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10450,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 6.3% (1/16) and stable disease in 87.5% (14/16) of patients with sporadic medullary thyroid carcinoma, with a median progression free survival of 17.9 months (PMID: 20368568).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3973,
                    "name": "thyroid medullary carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8463,
                        "pubMedId": 20368568,
                        "title": "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20368568"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7710,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial, Nexavar (sorafenib) treatment in non-small cell lung carcinoma patients did not reach its primary endpoint, resulting in an overall survival similar to that when treated with placebo, however, did meet its secondary endpoint, demonstrating a greater progression free survival and time to progression when compared to placebo (PMID: 26743856).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6454,
                        "pubMedId": 26743856,
                        "title": "Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743856"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 591,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, Nexavar (sorafenib) promoted apoptosis of endometrial carcinoma cells (PMID: 23463670).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2871,
                    "name": "endometrial carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 344,
                        "pubMedId": 23463670,
                        "title": "Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3\u03b2-dependent protein degradation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23463670"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1990,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) improved median progression free survival to 10.8 months in metastatic differentiated thyroid cancer patients (PMID: 24768112).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2438,
                        "pubMedId": 24768112,
                        "title": "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24768112"
                    },
                    {
                        "id": 15587,
                        "pubMedId": null,
                        "title": "Nexavar (sorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1004,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a meta-analysis of 844 ERBB2 (HER2)-negative breast cancer patients, Nexavar (sorafenib) increased progression-free survival time, but not overall survival or objective response rate (PMID: 24940450).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60080,
                    "name": "Her2-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 716,
                        "pubMedId": 24940450,
                        "title": "Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24940450"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 10439,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case report, Nexavar (sorafenib) therapy based on in vitro efficacy testing using patient-derived tumor cells resulted in 43 months of disease-free in a patient with anaplastic thyroid carcinoma (PMID: 27379749).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3963,
                    "name": "thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8451,
                        "pubMedId": 27379749,
                        "title": "Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27379749"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 1997,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) improved median progression free survival to 10.7 months in patients with unresectable hepatocellular carcinoma (PMID: 19144678).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2439,
                        "pubMedId": 19144678,
                        "title": "Sorafenib for the treatment of unresectable hepatocellular carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19144678"
                    },
                    {
                        "id": 15587,
                        "pubMedId": null,
                        "title": "Nexavar (sorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16307,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial, Nexavar (sorafenib) treatment resulted in an increased 2-year progression-free survival compared to placebo (81% vs 36%), an objective response rate of 33% (16/49; 1 complete response and 15 partial responses (PR)) compared in 20% (7/25; all PR) with placebo, and a median time to objective response of 9.6 months, compared to 13.3 months with placebo, in patients with refractory desmoid tumors (PMID: 30575484; NCT02066181).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 80366,
                    "name": "desmoid tumor",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 14419,
                        "pubMedId": 30575484,
                        "title": "Sorafenib for Advanced and Refractory Desmoid Tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30575484"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 7560,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Nexavar (sorafenib) and Torisel (temsirolimus) did not prolong progression-free survival compared to treatment with Avastin (bevacizumab) monotherapy (7.4 months vs 7.5 months) in patients with renal clear cell carcinoma (PMID: 26077237).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2388,
                    "therapyName": "Sorafenib + Temsirolimus",
                    "synonyms": null
                },
                "indication": {
                    "id": 4467,
                    "name": "clear cell renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6421,
                        "pubMedId": 26077237,
                        "title": "BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26077237"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            }
        ]
    },
    "variantAssociatedClinicalTrials": [
        {
            "nctId": "NCT03975231",
            "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03864042",
            "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7997,
                    "therapyName": "Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole",
                    "synonyms": null
                },
                {
                    "id": 7995,
                    "therapyName": "Modafinil",
                    "synonyms": null
                },
                {
                    "id": 7996,
                    "therapyName": "Bupropion + Rosuvastatin",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02693535",
            "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02382549",
            "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8248,
                    "therapyName": "6MHP vaccine + Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02130466",
            "title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1450,
                    "therapyName": "Pembrolizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1448,
                    "therapyName": "Dabrafenib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1449,
                    "therapyName": "Dabrafenib + Pembrolizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973918",
            "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03839342",
            "title": "Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02465060",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 654,
                    "therapyName": "AZD4547",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 660,
                    "therapyName": "Osimertinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 655,
                    "therapyName": "Capivasertib",
                    "synonyms": null
                },
                {
                    "id": 958,
                    "therapyName": "Defactinib",
                    "synonyms": null
                },
                {
                    "id": 765,
                    "therapyName": "GSK2636771",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        }
    ],
    "variantLevelEvidence": {
        "totalCount": 14,
        "variantLevelEvidences": [
            {
                "id": 12927,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600K, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 12835,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10781,
                        "pubMedId": 25399551,
                        "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15458,
                        "pubMedId": null,
                        "title": "Tafinlar (dabrafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16955,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and BRAF V600K are on the companion diagnostic.",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 11562,
                        "pubMedId": 29573941,
                        "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15455,
                        "pubMedId": null,
                        "title": "Braftovi (encorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                    },
                    {
                        "id": 15456,
                        "pubMedId": null,
                        "title": "Mektovi (binimetinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16951,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    },
                    {
                        "id": 15109,
                        "pubMedId": 30959471,
                        "title": "Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30959471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 16954,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 14457,
                        "pubMedId": 30219628,
                        "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15455,
                        "pubMedId": null,
                        "title": "Braftovi (encorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                    },
                    {
                        "id": 15456,
                        "pubMedId": null,
                        "title": "Mektovi (binimetinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 15734,
                "approvalStatus": "Clinical Study - Cohort",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival  (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13705,
                        "pubMedId": 30630828,
                        "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1508,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 12839,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 468,
                        "pubMedId": 22663011,
                        "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15457,
                        "pubMedId": null,
                        "title": "Mekinist (trametinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 5973,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15735,
                "approvalStatus": "Clinical Study - Cohort",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival  (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13705,
                        "pubMedId": 30630828,
                        "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 16949,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 15115,
                        "pubMedId": null,
                        "title": "ESMO Clinical Practice Guidelines",
                        "url": "https://www.esmo.org/Guidelines"
                    },
                    {
                        "id": 15431,
                        "pubMedId": 30715168,
                        "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                    },
                    {
                        "id": 15432,
                        "pubMedId": 30285222,
                        "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14665,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 12925,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 17035,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            },
            {
                "id": 12270,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
                "molecularProfile": {
                    "id": 2,
                    "profileName": "BRAF V600K"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10226,
                        "pubMedId": 27480103,
                        "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15453,
                        "pubMedId": null,
                        "title": "Cotellic (cobimetinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 14666,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14667,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14668,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600K"
                    },
                    {
                        "id": 14669,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600K"
                    }
                ]
            }
        ]
    }
}